Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesPhase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
Clinical Cancer Research, 10/01/09
Demetri GD et al. – Dasatinib was well tolerated in this population, with a safety profile similar to that observed previously in leukemia patients, although with much less hematologic toxicity. Limited, although encouraging, preliminary evidence of clinical activity was observed. Doses of 120 mg twice daily (5D2) or 70 mg twice daily (CDD) are recommended for further studies in patients with solid tumors.
Related Articles
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
British Journal of Cancer, 11/02/09
Relevance Score: 92%
Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Blood, 10/02/09
Relevance Score: 87%
Dasatinib-Induced Pleural Effusions: A Lymphatic Network Disorder
The American Journal of the Medical Sciences, 11/13/09
Relevance Score: 83%
A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells
Leukemia, 11/09/09
Relevance Score: 80%
Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification
Cancer Science, 10/08/09
Relevance Score: 80%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Valproic acid restores ERalpha and antiestrogen sensitivity to ERalpha-negative breast cancer cells
Molecular and Cellular Endocrinology, 11/25/09
N2 Disease in Patients With Head and Neck Squamous Cell Cancer Treated With Chemoradiotherapy
Archives of Otolaryngology, 11/25/09
Salvage treatment with upfront melphalan 100 mg/m2 and consolidation with novel drugs for fulminant progression of multiple myeloma
Annals of Hematology, 11/24/09
Today in Pharmacokinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients
Clinical Pharmacokinetics, 11/24/09
Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas
Clinical Cancer Research, 11/20/09
Safety Profile, Pharmacokinetics, and Pharmacodynamics of Siplizumab, A Humanized Anti-CD2 Monoclonal Antibody, in Renal Allograft Recipients
Transplantation Proceedings, 11/20/09
Sponsor
Article Search
Sponsor